A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Osoby w wieku 18 lat lub starsze.
  • Pacjenci z nawrotowym lub rozsianym rakiem, którzy byli już leczeni standardowymi metodami.
  • U pacjentów musi być możliwe zmierzenie zmian nowotworowych.
  • Stan ogólny pacjenta musi być dobry (nie powinien być zbyt osłabiony).
  • Przewidywana długość życia pacjenta to co najmniej 12 tygodni.
  • Wystarczająca wydolność szpiku kostnego, wątroby i nerek.
  • Potwierdzony typ nowotworu (np. rak piersi, jajnika, dróg żółciowych, trzonu macicy, płuca o typie płaskonabłonkowym) i stopień zaawansowania.
  • Minimalna waga ciała 30 kg (dla niektórych części badania).

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 16, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (67)

Research Site

Duarte, United States

Research Site

Irvine, United States

Research Site

Santa Monica, United States

Research Site

Santa Rosa, United States

Research Site

Shreveport, United States

Research Site

Baltimore, United States

Research Site

Boston, United States

Research Site

St Louis, United States

Research Site

Albuquerque, United States

Research Site

Commack, United States

Research Site

New York, United States

Research Site

Charlotte, United States

Research Site

Pittsburgh, United States

Research Site

Houston, United States

Research Site

Clayton, Australia

Research Site

Melbourne, Australia

Research Site

Nedlands, Australia

Research Site

Anderlecht, Belgium

Research Site

Leuven, Belgium

Research Site

Calgary, Canada

Research Site

Vancouver, Canada

Research Site

Ottawa, Canada

Research Site

Toronto, Canada

Research Site

Montreal, Canada

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changsha, China

Research Site

Changsha, China

Research Site

Chongqing, China

Research Site

Guangzhou, China

Research Site

Kunming, China

Research Site

Shandong, China

Research Site

Budapest, Hungary

Research Site

Budapest, Hungary

Research Site

Budapest, Hungary

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Modena, Italy

Research Site

Roma, Italy

Research Site

Chūōku, Japan

Research Site

Hidaka-shi, Japan

Research Site

Kashiwa, Japan

Research Site

Kōtoku, Japan

Research Site

Kurume-shi, Japan

Research Site

Sunto-gun, Japan

Research Site

Amsterdam, Netherlands

Research Site

Gdansk, Poland

Research Site

Warsaw, Poland

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

L'Hospitalet de Llobregat, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Bangkok, Thailand

Research Site

Chiang Mai, Thailand

Research Site

Cambridge, United Kingdom

Research Site

Cardiff, United Kingdom

Research Site

London, United Kingdom

Trial contact

AstraZeneca Clinical Study Information Center

AstraZeneca Breast Cancer Study Locator Service

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.